Spectral AI, Inc. 10-K

Item 8. Financial Statements and Supplementary Data The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Item 15, Exhibits and Financial Statement Schedules, of this Annual Report on Form 10-K. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure None. Item 9.A. Controls and Procedures. Evaluation of Disclosure Controls and Procedures Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Annual Report on Form 10-K. Material Weakness: Our financial statement close process controls, including controls over account reconciliations, transaction processing, and financial reporting review, did not operate consistently or with sufficient precision to ensure timely performance and review, including appropriate oversight of financial statement reporting. In conducting our evaluation, management used the updated framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Disclosure controls and procedures are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, management concluded that, as of December 31, 2025, our disclosure controls and procedures were not effective due to the material weakness in internal control over financial reporting described below. As discussed in Item 9A of our Form 10-K for the year ended December 31, 2025, we identified material weaknesses in our internal control over financial reporting as well as a lack of effective controls over the COSO principles including control environment, risk assessment, control activities, information and communications and monitoring as of December 31, 2025. 69 Remediation Plan for Material Weaknesses Remediation generally requires making changes to how controls are designed and implemented and then adhering to those changes for a sufficient period of time such that the effectiveness of those changes is demonstrated with an appropriate amount of consistency. In response to the material weakness, we implemented, and are continuing to implement and monitor, measures designed to improve our internal control over financial reporting. These efforts include: ● engaging a professional accounting services firm, in 2024, to help us assess and commence documentation of our internal controls for complying with the Sarbanes-Oxley Act of 2002; ● Engaged consultants to provide additional technical accounting expertise; ● During 2024 and 2025, enhanced functionality of our enterprise resource planning system to support certain key financial processes and controls and enforce certain segregation of duties through automation and approval workflows; and ● Improved accounting personnel by supplementing capacity gaps. We will continue to make additional accounting hires to further bolster capabilities. The measures we implemented are subject to continued management review supported by confirmation and testing, as well as audit committee oversight. Management and the Audit Committee remain committed to the implementation of remediation efforts to address the material weakness. We will continue to implement measures to remedy our internal control deficiencies, though there can be no assurance that our efforts will be successful or avoid potential future material weaknesses. In addition, until remediation steps have been completed and are operated for a sufficient period of time, and subsequent evaluation of their effectiveness is completed, the material weaknesses previously disclosed, and as described above, will continue to exist. Management’s Annual Report on Internal Control over Financial Reporting Our management, including our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated 2013 Framework. Based on this assessment, our management concluded that, as of December 31, 2025, our internal control over financial reporting was not effective at the reasonable assurance level, due to the material weaknesses outlined above. We made progress in 2025 to enhance and strengthen our internal control over financial reporting. The measures we implemented are subject to continued management review supported by confirmation and testing, as well as audit committee oversight. Management remains committed to remediating these material weaknesses. We will continue to implement measures to remedy our internal control deficiencies, though there can be no assurance that our efforts will be successful or avoid potential future material weaknesses. This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on internal control over financial reporting due to an exemption established by the JOBS Act for “emerging growth companies.” Changes in Internal Control over Financial Reporting Except for the remediation efforts in connection with the material weaknesses described above, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fourth quarter of the year ended December 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Item 9.B. Other Information. None . Item 9.C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection. Not Applicable. 70 PART III. Item 10. Directors, Executive Officers and Corporate Governance . The information required by this Item 10 is set forth under the captions “Executive Officers of the Registrant”, “Proposal No. 1 – Election of Directors” and “Board of Directors and Committees” in our Definitive Proxy Statement with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference. Item 11. Executive Compensation . As an “emerging growth company” as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have opted to comply with the scaled disclosure requirements applicable to emerging growth companies. The information required by this Item 11 is set forth under the caption “Executive Officer and Director Compensation” in our Definitive Proxy Statement with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters . The information required by this Item 12 is set forth under the captions “Share Ownership” and “Outstanding Equity Awards at Fiscal Year End 2025” in our Definitive Proxy Statement with respect to our 2026 Annual Meeting of Stockholders and is incorporated by reference. Item 13. Certain Relationships and Related Transactions, and Director Independence . The information required by this Item 13 is set forth under the captions “Certain Relationships and Related Transactions” and “Board of Directors and Committees” in our Definitive Proxy Statement with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference. Item 14. Principal Accountant Fees and Services . The information required by this Item 14 will be set forth under the caption “Proposal No. 2: Ratification of Independent Registered Public Accounting Firm” in our Definitive Proxy Statement with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference. 71 PART IV. Item 15. Exhibits, Financial Statement Schedules . (a) The following documents are filed as part of this Annual Report on Form 10-K: SPECTRAL AI, INC. INDEX TO FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 686 ) F-2 Report of Independent Registered Public Accounting Firm (PCAOB ID: 185) F-3 Consolidated Balance Sheets F-4 Consolidated Statements of Operations and Comprehensive Loss F-5 Consolidated Statements of Changes in Stockholders’ Equity (Deficit) F-6 Consolidated Statements of Cash Flows F-7 Notes to Consolidated Financial Statements F-8 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors Spectral AI, Inc. Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Spectral AI, Inc. (the “Company”) as of December 31, 2025, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity (deficit), and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. /s/ Forvis Mazars, LLP We have served as the Company’s auditor since 2025. Dallas, Texas March 24, 2026 F- 2 Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors Spectral AI, Inc.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Spectral AI, Inc. and subsidiaries (the Company) as of December 31, 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity (deficit), and cash flows for the year ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. We served as the Company’s auditor from 2021 to 2025. Dallas, Texas March 31, 2025 F- 3 SPECTRAL AI, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) December 31, December 31, 2025 2024 (1) Assets Current assets: Cash $ 15,394 $ 5,157 Accounts receivable, net 1,267 2,505 Inventory 838 425 Prepaid expenses 821 1,289 Other current assets 1,133 746 Total current assets 19,453 10,122 Non-current assets: Property and equipment, net 258 2 Right-of-use assets 1,407 1,971 Other assets 287 - Total Assets $ 21,405 $ 12,095 Commitments and contingencies (Note 7) Liabilities and Stockholders’ Equity (Deficit) Current liabilities: Accounts payable $ 3,010 $ 4,035 Accrued expenses 2,341 3,210 Deferred revenue 154 960 Lease liabilities, short-term 734 201 Notes payable 2,854 422 Notes payable – at fair value - 2,365 Warrant liabilities 11,533 6,451 Total current liabilities 20,626 17,644 Notes payable, long-term 5,538 - Lease liabilities, long-term 968 1,702 Total Liabilities 27,132 19,346 Stockholders’ Deficit Preferred stock ($ 0.0001 par value); 1,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and December 31, 2024 - - Common stock ($ 0.0001 par value); 80,000,000 shares authorized; 30,688,895 and 22,594,877 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively 3 2 Additional paid-in capital 50,030 40,973 Accumulated other comprehensive income 40 3 Accumulated deficit ( 55,800 ) ( 48,229 ) Total Stockholders’ Deficit ( 5,727 ) ( 7,251 ) Total Liabilities and Stockholders’ Deficit $ 21,405 $ 12,095 (1) Reflects an adjustment of $126,000 to additional paid-in capital and accumulated deficit as compared to previously reported amounts as of December 31, 2024. See further discussion in Note 1. The accompanying notes are an integral part of these consolidated financial statements F- 4 SPECTRAL AI, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) Year Ended December 31, 2025 2024 (1) Research and development revenue $ 19,650 $ 29,581 Cost of revenue ( 10,725 ) ( 16,307 ) Gross profit 8,925 13,274 Operating costs and expenses: General and administrative 17,528 19,856 Total operating costs and expenses 17,528 19,856 Operating loss ( 8,603 ) ( 6,582 ) Other income (expense): Net interest (expense) income ( 886 ) 14 Financing related costs ( 1,051 ) ( 2,965 ) Amortization of debt discount ( 455 ) - Change in fair value of warrant liabilities 3,249 ( 4,633 ) Change in fair value of notes payable 220 ( 220 ) Foreign exchange transaction loss, net ( 34 ) ( 43 ) Other expenses, including transaction costs - ( 615 ) Total other income (expense), net 1,043 ( 8,462 ) Loss before income taxes ( 7,560 ) ( 15,044 ) Income tax provision ( 11 ) ( 114 ) Net loss $ ( 7,571 ) $ ( 15,158 ) Net loss per share of common stock Basic and Diluted $ ( 0.29 ) $ ( 0.85 ) Weighted-average common shares outstanding Basic and Diluted 26,518,476 17,934,218 Other comprehensive income: Foreign currency translation adjustments $ 37 $ ( 9 ) Total comprehensive loss $ ( 7,534 ) $ ( 15,167 ) (1) Reflects an adjustment of $157,000 to the income tax provision during the year ended December 31, 2024. See further discussion in Note 1. The accompanying notes are an integral part of these consolidated financial statements F- 5 SPECTRAL AI, INC. CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (In thousands, except share data) Additional Accumulated Other Total Common Stock Paid-in Comprehensive Accumulated Stockholders’ Shares Amount Capital (1) Income Deficit (1) Deficit Balance at December 31, 2023 16,294,935 $ 2 $ 30,908 $ 12 $ ( 33,071 ) $ ( 2,149 ) Stock-based compensation - - 1,032 - - 1,032 Issuance of common stock under the SEPA 1,744,694 - 3,154 - - 3,154 Issuance of shares under convertible note - related party 540,996 - 1,422 - - 1,422 Sale of common stock 3,603,298 - 4,280 - - 4,280 Stock option exercises 281,857 - 177 - - 177 Vesting of restricted stock units 129,097 - - - - - Cumulative translation adjustment - - - ( 9 ) - ( 9 ) Net loss - - - - ( 15,158 ) ( 15,158 ) Balance at December 31, 2024 22,594,877 2 40,973 3 ( 48,229 ) ( 7,251 ) Stock-based compensation - - 1,115 - - 1,115 Sale of common stock and warrants (net of $158K issuance costs) 2,068,846 - 377 - - 377 Issuance of common stock to pay convertible debt 610,426 - 1,433 - - 1,433 Sale of common stock (net of $19K issuance costs) 310,925 - 543 - - 543 Sale of common stock and pre-funded warrants (net of $4K issuance costs) 3,065,000 1 48 - - 49 Exercise of stock options 525,277 - 889 - - 889 Vesting of restricted stock units 109,698 - - - - - Cumulative translation adjustment - - - 37 - 37 Warrant exercises 1,403,846 - 4,652 - - 4,652 Net Loss - - - - ( 7,571 ) ( 7,571 ) Balance at December 31, 2025 30,688,895 $ 3 $ 50,030 $ 40 $ ( 55,800 ) $ ( 5,727 ) (1) Reflects an adjustment of $126,000 as compared to previously reported amounts as of December 31, 2024. Reflects an adjustment of $(157,000) in Additional Paid in Capital and ($283,000) in Accumulated Deficit as of December 31, 2023. See further discussion in Note 1. The accompanying notes are an integral part of these consolidated financial statements F- 6 SPECTRAL AI, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Year Ended December 31, 2025 2024 (1) Cash flows from operating activities: Net loss $ ( 7,571 ) $ ( 15,158 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense 71 10 Amortization of debt issuance costs 454 - Stock-based compensation 1,115 1,032 Amortization of right-of-use assets 564 578 Change in fair value of warrant liabilities ( 3,249 ) 4,633 Change in fair value of notes payable ( 220 ) 220 Costs from issuance of common stock - 372 Issuance of shares for borrowing related costs 241 1,143 Transaction costs allocated to Avenue Warrants, Investor Warrants, and Hudson Warrants 704 - Changes in operating assets and liabilities: Accounts receivable 1,238 ( 159 ) Inventory ( 413 ) ( 195 ) Prepaid expenses 761 163 Other assets ( 387 ) ( 102 ) Accounts payable ( 1,025 ) 1,426 Accrued expenses ( 869 ) ( 1,090 ) Deferred revenue ( 806 ) ( 1,351 ) Lease liabilities ( 528 ) ( 721 ) Net cash used in operating activities ( 9,920 ) ( 9,199 ) Cash flows from financing activities: Proceeds from issuance of common stock and warrants 10,638 4,060 Payment of issuance costs ( 642 ) - Proceeds from notes payable 8,285 12,096 Payment of borrowing costs ( 47 ) - Proceeds from notes payable - related party - 1,000 Payments for notes payable ( 1,529 ) ( 7,758 ) Proceeds from warrant exercises 2,526 - Stock option exercises 889 177 Net cash provided by financing activities 20,120 9,575 Effect of exchange rate changes on cash 37 ( 9 ) Net increase in cash 10,237 367 Cash, beginning of period 5,157 4,790 Cash, end of period $ 15,394 $ 5,157 Supplemental cash flow information: Cash paid for interest $ 22 $ 11 Cash paid for taxes $ 100 $ 11 Noncash investing and financing activities disclosure: Recognition of Right-of-use assets and related lease liabilities upon lease amendment $ - $ 1,771 Tenant improvement allowance payments made by the lessor directly to a third party $ ( 327 ) $ - Issuance of common stock to settle accounts and notes payable $ 1,192 $ 3,207 Short-term financing of insurance premium $ ( 580 ) $ - (1) Reflects an adjustment of $157,000 to net loss and an adjustment of $(157,000) in the change in other assets during the year ended December 31, 2024. See further discussion in Note 1. F- 7 SPECTRAL AI, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. NATURE OF THE BUSINESS Business Combination Spectral AI, Inc., a Delaware corporation formerly known as Rosecliff Acquisition Corp I (“Spectral AI” or the “Company”) was formed as a blank check company on November 17, 2020. On September 11, 2023, the Company consummated a business combination (the “Business Combination”) pursuant to the business combination agreement dated April 11, 2023, by and among the Company, Ghost Merger Sub I, a Delaware Corporation, Ghost Merger Sub II, a Delaware corporation and Spectral MD Holdings, Ltd., a Delaware corporation. At the time of the Business Combination, 8,433,333 redeemable warrants issued to the public in Rosecliff Acquisition Corp I’s initial public offering (the “Public Warrants”) remained outstanding. On September 12, 2023, the Company began trading the Company Common Stock and the Public Warrants on the NASDAQ Capital Market (“NASDAQ”) under the symbols “MDAI” and “MDAIW”, respectively. Prior to the Business Combination, the Company’s shares of Company Common Stock and Public Warrants were listed on the NASDAQ under the symbols “RCLF” and “RCLFW”, respectively. Nature of Operations We are an artificial intelligence (“AI”) company focused on predictive medical diagnostics. Our DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wounds capacity to heal by a specified time point in the future. Our DeepView System’s output is specifically engineered to assist the physician in making a more accurate, timely and informed decision regarding the treatment of the patient’s wounds. Spectral AI is devoting substantially all of its efforts towards research and development of its DeepView Wound Imaging System, currently focused on burn wounds, specifically engineered to allow physicians to make a more accurate, timely and informed decision for treatment options. The Company has not generated any product revenue to date. The Company currently generates revenue from contract development and research services by providing such services to governmental agencies, primarily to the Biomedical Advanced Research and Development Authority (“BARDA”) and under a contract with Medical Technology Enterprise Consortium (“MTEC”). In September 2023, the Company executed its third contract with BARDA for a multi-year Project BioShield (“PBS”) contract, valued at up to approximately $ 150.0 million (the “PBS BARDA Contract”). This multi-year contract includes an initial award of nearly $ 54.9 million to support the clinical validation and FDA clearance of our DeepView System for commercial development and distribution purposes. The PBS BARDA Contract also includes options, similar to our prior BARDA contracts, with an additional total value of approximately $ 95.1 million which can be exercised for additional product development, procurement and the expanded deployment of DeepView Systems at emergency rooms, trauma and burn centers. The Company completed the second contract with BARDA, referred to as BARDA Burn II, which was signed in July 2019 and completed in November 2023. Under this contract, the Company furthered the DeepView System design, developed the AI algorithm, and took steps to obtain FDA approval. As of December 31, 2025, the Company has $ 5.3 million remaining to bill under the initial award under the PBS BARDA Contract. In April 2023, the Company received a $ 4.0 million grant from MTEC for a project that is expected to be completed in 2026 (the “MTEC Agreement”). The MTEC Agreement is for the development of a handheld version of the DeepView System which is to be used to support military battlefield burn evaluation. The project has three phases, beginning with planning, design and testing; followed by development, design modification and buildout of the handheld device; and then the manufacturing of the handheld device. In August 2024, the MTEC award was increased to $ 4.9 million and was extended to run through December 2025 with funding dependent on various milestones. In December 2025, the MTEC contract was extended to run through June 2026. In March 2024, we received an additional $ 0.5 million award from the Defense Health Agency to further this development. As of December 31, 2025, the Company has $ 1.6 million and $ 0.05 million remaining to bill under the MTEC and DHA awards, respectively. F- 8 On March 7, 2024, the Company formed a new wholly-owned subsidiary, Spectral IP, Inc., a Delaware corporation (“Spectral IP”), to be utilized to advance artificial intelligence intellectual property with a specific emphasis on healthcare. On March 19, 2024, the Company announced that Spectral IP received a $ 1.0 million investment from an affiliate of its largest shareholder for the development of its artificial intelligence intellectual property portfolio. The investment is structured as a note payable with a one-year maturity, an interest rate of 8 %, and requiring earlier prepayment if the Company spins off Spectral IP to the Company’s shareholders or if Spectral IP is sold to a third party. On October 1, 2024, the note was amended to (i) reduce the annual interest rate from 8 % to 4 %, (ii) extend the term of the note through the second anniversary of the issuance date, March 18, 2026, (iii) include a conversion feature at the option of either the holder or Spectral IP to convert the then outstanding principal and accrued but unpaid interest into shares of the Company at any time (into such number of shares calculated by taking a five percent ( 5.00 %) discount to the closing price of the Company’s common stock on the day prior to the date of notice to the Company of the exercise of the conversion right) and at maturity, respectively, and (iv) provide for registration rights of any shares of the Company issued in satisfaction of the outstanding obligations. On October 1, 2024, Spectral IP amended its existing $ 1,000,000 promissory note to extend the term from one to two years , reduce the interest rate from 8.00 % to 4.00 % per annum and to provide a conversion feature for shares of the Company’s common stock in satisfaction of the outstanding principal and accrued but unpaid interest. The holder of the Spectral IP Note exercised a number of conversion rights throughout the fourth quarter of 2024 for the full conversion of the Spectral IP Note in exchange for a total of 540,996 shares of the Company’s common stock, which represents a 5.00 % discount to the closing price of the Company’s shares of Common Stock on the day prior to the date of notice of the holder’s exercise of its conversion right Revision of Prior Period Financial Information As previously disclosed, during the year ended December 31, 2023, management deferred certain costs associated with a stock offering which was completed during 2024, at which time the costs were recorded as a reduction of additional paid-in capital. Management subsequently determined that these costs should have been expensed during the fourth quarter of 2023. Accordingly, the Company has revised its consolidated statements of changes in stockholders’ equity (deficit) as of December 31, 2024, and 2023 to increase both the accumulated deficit and additional paid-in capital by $ 283,000 . Additionally, during the third quarter of 2023 in conjunction with the accounting for the Business Combination, the Company recognized an income tax receivable asset which should not have been recorded due to uncertainties about collectability. This receivable was written off during the fourth quarter of 2024 through income tax expense. Accordingly, the Company has revised its consolidated statement of changes in stockholders’ deficit to reduce both the accumulated deficit and additional paid-in capital by $ 157,000 as of December 31, 2024 and to reduce additional paid in capital by $ 157,000 as of December 31, 2023. The Company has revised its consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 to reduce income tax provision and net loss by $ 157,000 and to revise the net loss per share accordingly as well. The net effect of the two corrections described above is a $ 126,000 increase to both the accumulated deficit and additional paid-in capital as of December 31, 2024, and 2023. The Company has determined that the errors were immaterial to all impacted periods and has corrected the impacted periods as an immaterial correction of an error. F- 9 Risks and Uncertainties The Company is subject to a number of risks common to development stage companies in the medical technology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any products that it may develop, development by competitors of technological innovations, compliance with government regulations and the need to obtain additional financing. Liquidity As of December 31, 2025 the Company had approximately $ 15.4 million in cash, and an accumulated deficit of $ 55.8 million. As of December 31, 2025, the Company had approximately $ 8.4 million in notes payable, of which $ 5.5 million is long-term. See Note 6. On March 24, 2025, the Company completed an equity financing and entered into a long-term debt financing agreement with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (the “Avenue Financing”), which provides for the ability to borrow up to $ 15.0 million with an initial draw-down of $ 8.5 million, and the remaining availability is contingent upon, among other things, FDA clearance of the DeepView System, see Note 6. On October 22, 2025, the Company entered into a securities purchase agreement, by and between Spectral AI, Inc. and Hudson Bay Master Fund Ltd., which provided for the issuance and sale of 3.1 million shares of Common Stock, at an offering price of $ 1.90 per share. In addition, in a concurrent private placement, the Company issued and sold warrants for the purchase of up to 4.0 million shares of Common Stock and pre-funded warrants to purchase up to 0.9 million shares of common stock, for aggregate gross proceeds of $ 7.6 million (such transaction, the “Hudson Bay Financing”). Each warrant has an exercise price per share of $ 2.51 and will be exercisable on the earlier of (a) the effective date of stockholder approval for the issuance of shares of Common Stock underlying the warrants and (b) the date that is six months following the issuance date of the warrants and will have a term of five (5) years from the initial issuance date.. See Note 2 for further information. On March 18, 2026, the Company announced that it has received a contract modification from BARDA for the advancement of $ 31.7 million from its existing contract with BARDA which included (i) a no-cost extension of the base phase of the contract, and (ii) the acceleration of certain parts of the next phase of such contract. As part of this funding advance, the Company has committed to fund $ 9.7 million of the total overall development costs associated with these feature advancements. This funding comes as part of an ongoing partnership with BARDA, which has committed $ 54.9 million to date under the contract with an overall value of approximately $ 150 million. As of December 31, 2025, based on our current operating plan, we believe that our cash and cash equivalents, together with the PBS BARDA Contract, the MTEC Agreement, the Avenue Financing, the Hudson Bay Financing, the Yorkville SEPA and certain research and development cost-saving measures, the Company believes it has, sufficient working capital to fund operations for at least one year beyond the release date of the consolidated financial statements. We have based this determination on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Changing circumstances could also cause us to consume capital significantly faster than we currently anticipate, and we may need to raise capital sooner or in greater amounts than currently expected because of circumstances beyond our control. To the extent additional capital is necessary, there are no assurances that we will be able to raise additional capital on favorable terms or at all, and therefore we may not be able to execute our business plans and the continued work on indications beyond expanding our burn indication. F- 10 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) or an Accounting Standards Update (“ASU”). Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Spectral MD Holdings LLC, Spectral MD Inc., Spectral MD UK Limited (“Spectral MD UK”), Spectral IP, Inc. and Spectral DeepView Limited. Spectral DeepView Limited was dissolved in February 2026. Significant inter-company transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition (including the measure of progress of completion), warrant liabilities, the fair value of short term notes payable, fair value of the B. Riley and Yorkville derivative instruments, stock-based compensation expense, stock issued for transaction costs, the net realizable value of inventory, right-of-use assets, and income tax valuation allowances. Actual results could differ from these estimates. Segments Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Chairman of the Board in conjunction with the Company’s executive management team manages the Company’s operations on an aggregate basis for the purpose of allocating resources. The Company has one operating segment. The accounting policies of the Company’s single operating and reportable segment are the same as those described in the summary of significant accounting policies. The Company’s method for measuring profitability includes net income (loss), which the chief operating decision-maker uses to assess performance and make decisions for resource allocation, consistent with the measurement principals for net income(loss) as reported on the Company’s consolidated statement of operations. The significant expenses regularly reviewed by the chief operating decision-maker are consistent with those reported on the Company’s consolidated statement of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources. The measure of segment assets is reported on the consolidated balance sheets as total assets. Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash is held in US and UK financial institutions. Accounts Receivable Accounts receivable represent amounts due from US government agencies pursuant to research and development contracts associated with the Company’s DeepView System. F- 11 The Company evaluates the collectability of its receivables based on a variety of factors, including the length of time the receivables are past due, the financial health of its customers and historical experience. Based upon the review of these factors, the Company recorded no allowance for credit losses as of December 31, 2025 and December 31, 2024. Certain third-party costs that are prepaid per the terms of the contract are billable to customers prior to recognition of related expenses. The Company records deferred revenue when the customers have been billed prior to recognizing revenue. Comprehensive Loss Comprehensive loss includes net loss, as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist principally of cash and accounts receivable. Primarily all cash is held in US financial institutions which, at times, exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company believes it is not exposed to significant credit risk on cash. Additional credit risk is related to the Company’s concentration of receivables. As of December 31, 2025 and December 31, 2024, receivables were concentrated from one customer (which is a US. government agency) representing 100 % and 85 % of total net receivables, respectively. One customer (which is a U.S. government agency) accounted for 90 % for the year ended December 31, 2025 and 94 % for the year ended December 31, 2024 of the recognized research and development revenue. Inventory Inventory is comprised of finished goods, purchased from a third-party manufacturer, and is stated at the lower of cost (average cost) or net realizable value. For the year ended December 31, 2025, the Company did not have write-downs for obsolete inventory. Fair Value Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 Unadjusted quoted prices in active markets that are assessable at the measurement date for identical, unrestricted assets or liabilities. Level 2 Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). F- 12 Foreign Currency The reporting currency for the consolidated financial statements of the Company is the US dollar. The functional currency of the Company and its wholly-owned subsidiaries Spectral MD Holdings LLC, Spectral MD, Inc., and Spectral IP is the US dollar. The functional currency of Spectral MD UK is its local currency, the British pound. The functional currency of Spectral DeepView Limited was its local currency, the Euro. The assets and liabilities of Spectral MD UK and Spectral DeepView Limited, are translated into US. dollars at exchange rates in effect at the end of each reporting period, and the revenues and expenses are translated at average exchange rates in effect during the applicable reporting period. Spectral DeepView Limited was dissolved in February 2026. Translation adjustments are included in accumulated other comprehensive income as a component of stockholders’ equity. As of December 31, 2025 and December 31, 2024, the Company’s translation adjustments are not material. Monetary assets and liabilities denominated in currencies other than the US dollar are translated at exchange rates in effect as of the balance sheet date. Resulting unrealized gains and losses are included in other income (expense), net in the consolidated statements of operations. For the year ended December 31, 2025, the Company recorded approximately $ 34 ,000 of net foreign exchange transaction losses. For the year ended December 31, 2024, the Company recorded approximately $ 43 ,000 of net foreign exchange transaction losses. These amounts primarily relate to one of the Company’s bank accounts being denominated in British Pounds and certain accounts payable denominated in British Pounds. Property and Equipment, Net Property and equipment, net is recorded at cost less accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful lives of the related assets, which are as follows: Estimated Useful Life Computer equipment 3 years Manufacturing equipment 5 years Furniture and equipment 5 years Laboratory equipment 5 years Leasehold improvements Shorter of remaining lease term or useful life Depreciation expense for the years ended December 31, 2025 and 2024 was $ 71 ,000 and $ 10 ,000, respectively. Purchased assets that are not yet in service are recorded to construction-in-process and no depreciation expense is recorded. Once they are placed in service, they are reclassified to the appropriate asset class. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the Company’s consolidated statements of operation and comprehensive loss. Expenditures for maintenance and repairs are expensed as incurred. Impairment of Long-Lived Assets Long-lived assets consist of property and equipment. The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may not be recoverable. If circumstances require that a long-lived asset or asset group be tested for impairment, the Company first compares the estimated undiscounted future cash flows expected to result from the use or disposition of that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment loss would be recognized to the extent the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market prices and third-party independent appraisals, as considered necessary. F- 13 Leases Under lease guidance, arrangements meeting the definition of a lease are classified as operating or financing leases. Operating leases are recorded in the consolidated balance sheets as both a right-of-use asset and a lease liability, calculated by discounting fixed lease payments at the rate implicit in the lease or the Company’s incremental borrowing rate factoring the term of the lease. The incremental borrowing rate used by the Company is an estimate of the interest rate the Company would incur to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease. Because the Company does not generally borrow on a collateralized basis, it uses the interest rate it pays on its noncollateralized borrowings as an input to deriving an appropriate incremental borrowing rate, adjusted for the amount of lease payments, the lease term and the effect on that rate of designating specific collateral with a value equal to the unpaid lease payments for that lease. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right-of-use assets and lease liabilities, the Company has elected to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the requirement to capitalize right-of-use assets and liabilities as an accounting policy election. During the years ended December 31, 2025 and 2024, the Company did not have any financing leases. Warrant Liabilities Public Warrants : On September 11, 2023, in conjunction with the Business Combination, the Company assumed the Public Warrants which had an exercise price of $ 11.50 per share, are exercisable 30 days after the Business Combination and expire five years after the Business Combination or upon redemption. The Company may redeem the Public Warrants if the Company’s common stock equals or exceeds $ 18.00 per share for 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the holders of Public Warrants. In November 2024, the Company amended the Public Warrants to have an exercise price of $ 2.75 per share. As of December 31, 2025, there are 8,433,333 Public Warrants Outstanding. Each warrant entitles the registered holder to purchase one share of Company Common Stock at an exercise price of $ 2.75 per full share. Pursuant to the Warrant Agreement, a holder of Public Warrants may exercise its Public Warrants only for a whole number of shares of Company Common Stock. This means that only a whole warrant may be exercised at any given time by a holder of Public Warrants. The Company maintains a redemption right with respect to the Public Warrants in that the Company can redeem some or all of the Public Warrants for $ 0.10 per Public Warrant based on certain market conditions and the market price of the Company Common Stock. Angel Warrants : In September 2021, Legacy Spectral issued 73,978 warrants, with a strike price of $ 7.75 and a five-year life, to SP Angel Corporate Finance LLP (“SP Angel”), who acted as nominated adviser and broker to the Company for the purposes of the AIM Rules (“Angel Warrants”). In conjunction with the Business Combination, the Angel Warrants were converted into warrants to purchase Company Common Stock based on the Exchange Ratio. As of December 31, 2025, there are 73,978 Angel Warrants to purchase Company Common Stock outstanding. The Company accounts for its Public Warrants and the Angel Warrants as derivative liabilities. Accordingly, the Company recognizes the instruments as liabilities at fair value, determined using the closing price of the observable market quote in an active market (the NASDAQ) for the Public Warrants and the Black-Scholes option-pricing model for the Angel Warrants, and adjusts the instruments to fair value at the end of each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, redeemed or expired, and any change in fair value is recognized in the Company’s consolidated statements of operations within other income (expense). Investor Warrants : On March 21, 2025, the Company entered into purchase agreements with certain stockholders for the sale of an aggregate of 2,068,846 shares of Common Stock, at an offering price of $ 1.30 per Share (the “Purchase Agreements”). In a concurrent private placement pursuant to the Purchase Agreements (the “Private Placement”), the Company agreed to sell to the investors an aggregate of 2,068,846 warrants to purchase shares of Common Stock at an exercise price of $ 1.80 per share (the “Investor Warrants”). The Investor Warrants, along with the shares of Common Stock issuable upon the exercise of the Investor Warrants, were offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”). No consideration was received by the Company for the issuance of the Investor Warrants. F- 14 The Investor Warrants issued in connection with the Purchase Agreements are exercisable any time on or after March 20, 2025 (the “Issuance Date”) and on or prior to the close of business on the third anniversary of the Issuance Date. Additionally, the Investor Warrants issued in connection with the Purchase Agreements contain adjustment provisions in the event of (i) stock dividends and split, (ii) reclassifications of securities, (iii) issuance of Common Stock or Common Stock Equivalents (as defined in the Purchase Agreements), (iv) pro rata distributions, (v) Fundamental Transactions (as defined in the Warrants), and (vi) subsequent equity sales of shares of common stock or common stock equivalents for a consideration per share less than a price equal to $ 1.30 , subject to a floor of $ 0.65 per share. The Investor Warrants issued in connection with the Purchase Agreements also include a “Most Favored Nation” clause which grants the holders of such Investor Warrants the right, in their sole discretion, to elect to receive more favorable terms and conditions given to a subsequent investor in a subsequent financing transaction (including, but not limited to, a lower purchase price per share, a higher warrant coverage percentage, a lower warrant exercise price, a longer warrant exercise period, more favorable anti-dilution protections, preferential liquidation rights, enhanced voting rights, reduced fees or commissions, more advantageous registration rights, or the inclusion of additional incentives such as cash bonuses, dividend preferences, or equity sweeteners). The Investor Warrants were determined to be liability classified instruments, as certain terms preclude them from being considered indexed to the Company’s Common Stock. The gross proceeds of the Private Placement and Investor Warrants of $ 2.7 million were allocated to the Investor Warrants based on their fair value at issuance of $ 2.2 million, with the residual gross proceeds of $ 0.5 million allocated to the Common Stock. Total issuance costs incurred of $ 0.2 million were allocated between the Investor Warrants and Common Stock issued. Issuance costs allocated to the Investor Warrants of $ 43,000 were expensed during the year ended December 31, 2025 as financing related costs in the consolidated statement of operations and comprehensive loss. Issuance costs allocated to the Common Stock of $ 152,000 were recorded in additional paid-in-capital. In May 2025, 915,000 Investor Warrants, (the “Amended Investor Warrants”) were amended and restated. The amendment extended the contractual term such that the Amended Investor Warrants are exercisable any time on or prior to the close of business on the fifth anniversary of the Issuance Date and resulted in $ 137,000 increase in the fair value of the warrants recognized as additional expense in the change in fair value of warrant liabilities in the consolidated statement of operations and comprehensive loss. During the year ended December 31, 2025, 1,403,846 Investor Warrants were exercised. The warrants were remeasured to fair value immediately prior to exercise and the carrying amount of the warrant liability was derecognized and reclassified to additional paid-in-capital. Any proceeds received from exercise were recognized in stockholders’ equity. The exercise of warrants resulted in an increase to stockholders’ equity of $ 4.7 million. As of December 31, 2025, there were 665,000 Investor Warrants to purchase Common Stock outstanding. Avenue Warrants: On March 24, 2025, the Company completed the Avenue Financing, with an initial draw-down of $ 8.5 million. As part of the Avenue Financing the Company issued 768,072 warrants to Avenue Capital Group which was equal to 8.5 % of the total funding commitment (the “Avenue Warrants”). The Avenue Warrants have an exercise price equal to the lower of $ 1.66 per share and the lowest price per share paid to the Company in cash for common stock through December 31, 2025. The Avenue Warrants were determined to be classified as a liability instrument as certain terms preclude them from being considered indexed to the Company’s Common Stock. The net proceeds of Avenue Financing of $ 8.3 million were first allocated to the fair value of the Avenue Warrants, with the residual proceeds being allocated to the debt. The difference between debt proceeds and the amount of those proceeds allocated to debt gave rise to a debt discount of $ 0.7 million. The discount amount due to the Avenue Warrants of $ 0.7 million along with the loan fees allocated to the loan of $ 1.0 million, which includes the final payment of $ 0.8 million, for an aggregate debt discount and debt issuance costs of $ 1.7 million, will be amortized as interest expense through maturity using the effective interest method. The portion of loan fees allocated to the Avenue Warrants, of $ 22,000 , were expensed during the year ended December 31, 2025 as financing related costs in the consolidated statement of operations and comprehensive loss. As of December 31, 2025, there were 768,072 Avenue Warrants to purchase Common Stock outstanding. Hudson Warrants: On October 22, 2025, the Company entered into a securities purchase agreement with a certain investor for the sale of 3,065,000 shares of Common Stock, at an offering price of $ 1.90 per Share (the “Offering”). In a concurrent private placement pursuant to the purchase agreement, the Company agreed to sell to the investor (i) warrants (the “Hudson Warrants”) to purchase up to 4,000,000 shares of Common Stock, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 935,000 shares of Common Stock. Each Hudson Warrant has an exercise price per share of $ 2.51 , will exercisable on the earlier of (a) the effective date of stockholder approval for the issuance of shares of Common Stock underlying the warrants and (b) the date that is six months following the issuance date of the warrants and will have a term of five years from the initial issuance date. Each Pre-Funded Warrant has a purchase price of $ 1.8999 , an exercise price per share of $ 0.0001 , is exercisable immediately and may be exercised at any time until such Pre-Funded Warrant is exercised in full. The Hudson Warrants and the Pre-Funded Warrants, along with the shares of Common Stock issuable upon the exercise of the warrants, are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act of 1933, as amended. F- 15 The Hudson Warrants and Pre-Funded Warrants contain adjustment provisions in the event of (i) stock dividends and split, (ii) pro rata distributions, and (iii) Fundamental Transactions (as defined in the warrant agreements). In the event of a Fundamental Transaction not in the Company’s control, the holders of the Warrants have the right to require the Company or a successor entity to redeem the Hudson Warrants for cash in the amount of the Black Scholes Value (as defined in the warrant agreements). The Hudson Warrants contain further adjustment provisions in the event of the (i) subsequent equity sales of shares of common stock or common stock equivalents for a consideration per share less than a price equal to $2.51 (ii) changes in the exercise price or rate of conversion of equity sales or convertible securities any time prior to the two-year anniversary of the stockholder approval date, subject to a floor of $ 0.48 per share. The Hudson Warrants were determined to be liability classified instruments, as certain terms preclude them from being considered indexed to the Company’s Common Stock. The Pre-Funded Warrants were determined to be equity classified instruments, as they are considered indexed to the Company’s stock and do not contain any provisions that preclude equity classification. The gross proceeds of the Offering and private placement of $ 7.6 million were allocated to the Hudson Warrants based on their fair value at issuance of $ 7.5 million, with the residual gross proceeds of $ 0.1 million allocated between the Common Stock and Pre-Funded Warrants based on their relative fair value. Total issuance costs incurred of $ 0.6 million were allocated between the warrants and Common Stock issued. Issuance costs allocated to the Hudson Warrants of $ 0.6 million were expensed during the year ended December 31, 2025 as financing related costs in the consolidated statement of operations and comprehensive loss. Issuance costs allocated to the Common Stock and Pre-Funded Warrants of less than $ 0.1 million were recorded in additional paid-in-capital. As of December 31, 2025, there were 4,000,000 Hudson Warrants and 935,000 Pre-Funded Warrants to purchase Common Stock outstanding. Research and Development Revenue The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. ASC 606 requires the Company to identify the contract with a customer, identify the performance obligations, determine and allocate the transaction price, and recognize revenue when, or as, performance obligations are satisfied. The Company generates research and development revenue primarily from contracts with the Biomedical Advanced Research and Development Authority (“BARDA”) and the Medical Technology Enterprise Consortium (“MTEC”). Each of the Company’s BARDA and MTEC arrangements contains a single performance obligation. The Company’s contract with BARDA is a cost-plus-fee arrangement related to the research, development, clinical validation, regulatory advancement and commercialization of the Company’s DeepView® System, which represents an output of the Company’s ordinary activities. Accordingly, the Company has concluded that BARDA is a customer within the scope of ASC 606. Under these arrangements, BARDA reimburses the Company for allowable costs incurred which are subject to contractual ceilings. Costs are reimbursed under the incurred costs method of inputs for satisfying obligations over time that are allowable under the contract. The contract contains a single performance obligation consisting of a bundled promise to perform research and development activities necessary to develop and advance the DeepView® System. The Company has determined that the BARDA contracts do not contain a financing component. Under the contract, BARDA receives a non-exclusive, non-transferable, irrevocable, paid-up license to use the technology developed under the agreements, along with certain restrictions on the Company’s ability to transfer the developed technology and a right of first refusal in the event of a proposed sale for devices licensed under the agreement. While the Company retains ownership of the underlying intellectual property, these provisions provide BARDA with substantive and enforceable rights to the outputs of the Company’s research and development activities, supporting the conclusion that the arrangements are contracts with a customer under ASC 606 F- 16 We receive funding from a contract by the DHA within the U.S. Department of Defense, which enables us to research and develop a fully portable, handheld version of our DeepView System. We were previously awarded a $ 1.1 million Sequential Phase II STTR contract by the DHA within the U.S. Department of Defense, which is paid to us monthly, as well as a STTR Phase I and initial Phase II contract from the DHA. In December 2025, the MTEC contract was extended through June 2026. The MTEC Agreement provides for installment payments after the completion of milestone events. The installment payments are considered variable consideration as the entitlement depends on successful completion of research. However, the payments are not constrained from inclusion in the transaction price as it not probable that a significant reversal of cumulative revenue will be reversed when the underlying uncertainty is resolved. Revenue for the MTEC Agreement is recognized over time based upon the cost-to-cost measure of progress, using this input method to measure progress as the customer has the benefit of access to the development research under these projects and therefore benefits from the Company’s performance incrementally as research and development activities occur under each project. The Company measures progress of performance by comparing the actual costs incurred to-date to the total estimated cost of the project. The Company will adjust the measure of progress at the end of each reporting period and reflect any changes to the estimated cost of the project on a prospective basis. The Company records unbilled revenue when revenue is recognized prior to billing. As of December 31, 2025, the Company had approximately $ 1.6 million of billings remaining in 2026. The Company elected the practical expedient not to adjust the transaction price for the effects of a significant financing component as the period between performance (satisfaction of a performance obligation) and payment is one year or less. Payments from customers are generally received within 30 days of when the invoice is sent. Research and Development Expense The Company expenses research and development costs as incurred. These expenses include salaries for research and development personnel, consulting fees, product development, pre-clinical studies, clinical trial costs, and other fees and costs related to the development of the technology. For the years ended December 31, 2025 and 2024, research and development expense was $ 11.3 million and $ 19.3 million, respectively, of which $ 10.7 million and $ 16.1 million, respectively, is related to the combined BARDA, DHA and MTEC contracts and included in cost of revenue and $ 0.6 million and $ 3.2 million, respectively, is included in general and administrative expenses. Stock-Based Compensation The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options and RSUs based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSUs are valued based on the fair value of the Company’s common stock on the date of grant. The fair value of RSUs with market based vesting conditions were determined using a Monte-Carlo Simulation to reflect the effects of the market conditions. The assumptions used in calculating the fair value of the Company’s stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company expenses stock-based compensation related to stock options and RSUs over the requisite service period. Forfeitures are recorded as they occur. Compensation previously recorded for unvested equity awards that are forfeited is reversed upon forfeiture. The Company expenses stock-based compensation to employees over the requisite service period, on a straight-line basis, based on the estimated grant-date fair value of the awards. For RSUs with market-based conditions, compensation is not reversed if these awards are forfeited based solely on failing to meet such market-based conditions. Income Taxes The Company records its deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. F- 17 When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company has no uncertain tax positions as of December 31, 2025 and December 31, 2024 that qualify for either recognition or disclosure in the consolidated financial statements under this guidance. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations. The Company did not have any interest and penalties during the years ended December 31, 2025 and 2024 and did not have any interest or penalties accrued as of December 31, 2025. Net Loss per Share of Common Stock Basic net loss per share of common stock is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock adjusts basic earnings per share for the potentially dilutive impact of unvested restricted stock, stock options and warrants. Securities having an anti-dilutive effect on diluted net earnings per share are excluded from the calculation. The dilutive effect of the unvested restricted stock and stock options is calculated using the treasury stock method. For warrants that are liability-classified, during periods when the impact is dilutive, the Company assumes share settlement of the instruments as of the beginning of the reporting period and adjusts the numerator to remove the change in fair value of the warrant liability and adjusts the denominator to include the dilutive shares calculated using the treasury stock method. Comprehensive Income (Loss) Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income (loss) disclosures, the Company does not record deferred taxes for the net changes in the foreign currency translation adjustment, as it intends to indefinitely reinvest undistributed earnings of its foreign subsidiaries. Accumulated other comprehensive income (loss) is reported as a component of stockholders’ equity. Recently Adopted Accounting Standards In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires more detailed income tax disclosures, requiring entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The Company adopted this guidance prospectively in the year ended December 31, 2025 with no material impact on the consolidated financial statements and disclosures, see Note 11 for additional information. Recently Issued Accounting Standards In October 2023, the FASB issued ASU 2023-06 Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”), which modifies certain disclosure and presentation requirements of a variety of Topics in the Codification and is intended to both clarify or improve such requirements and align the requirements with the SEC’s regulations. The effective date for each amendment is the effective date of the removal of the related disclosure from Regulation S-X or Regulation S-K, with early adoption prohibited. The Company will apply the provisions prospectively as such provisions become effective and does not expect ASU 2023-06 to have a material impact on the consolidated financial statements. F- 18 In November 2024, the FASB issued ASU No. 2024-03, Income Statement- Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40), requiring public business entities to disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The disclosures required under the guidance can be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements and disclosures. In July 2025, the FASB issued ASU No. 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets, (“ASU 2025-05”) which provides a practical expedient to measure credit losses on accounts receivable and contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting periods within those fiscal years, with early adoption permitted. The Company does not expect ASU 2025-05 to have a material impact on the consolidated financial statements and related disclosures. 3. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s financial liabilities that are measured at fair value on a recurring basis as of December 31, 2025 and December 31, 2024, by level within the fair value hierarchy (in thousands): Fair value measured as of December 31, 2025 Quoted prices Significant other Significant Fair value at December 31, 2025 in active markets (Level 1) observable inputs (Level 2) unobservable inputs (Level 3) Warrant liabilities $ 11,533 3,795 - 7,738 $ 11,533 3,795 - 7,738 Fair value measured as of December 31, 2024 Quoted prices Significant other Significant Fair value at December 31, 2024 in active markets (Level 1) observable inputs (Level 2) unobservable inputs (Level 3) Warrant liabilities $ 6,451 $ 6,410 $ - $ 41 Short-term notes payable- Yorkville 2,365 - - 2,365 $ 8,816 $ 6,410 $ - $ 2,406 There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2025 and 2024. Fair values of cash, accounts receivable, accounts payable, accrued expenses, and short-term debt are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The fair value of the Public Warrants, which trade in active markets, is based on quoted market prices and classified in Level 1 of the fair value hierarchy. The Angel Warrants, Avenue Warrants, Investor Warrants and Hudson Warrants are classified within Level 3 of the fair value hierarchy because their fair values are based on significant inputs that are unobservable in the market. F- 19 The following table presents changes in Level 3 warrant liabilities measured at fair value for the years ended December 31, 2025 and 2024 (in thousands): Balance - January 1, 2024 $ 47 Change in fair value ( 6 ) Balance - January 1, 2025 $ 41 Issuance of warrants 10,456 Exercise of warrants ( 2,125 ) Change in fair value ( 634 ) Balance - December 31, 2025 $ 7,738 Both observable and unobservable inputs were used to determine the fair value of warrants that the Company has classified within the Level 3 category. Unrealized gains and losses associated with warrant liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs. The following table provides quantitative information regarding Level 3 warrant liability fair value measurements inputs at their measurement: December 31, 2025 December 31, 2024 Angel Warrants  Investor Warrants Avenue Warrants Hudson Warrants Angel Warrants Valuation Method Black Scholes Monte Carlo Black Scholes Monte Carlo Black Scholes Strike price (per share) $ 7.32 $ 1.80 $ 1.66 $ 2.51 $ 7.32 Contractual term (years) 1.5 4.2 3.5 4.8 2.5 Volatility (annual) 92.1 % 80.0 % 79.0 % 70.0 % 70.6 % Risk-free rate 3.5 % 3.6 % 3.6 % 3.6 % 4.3 % Dividend yield (per share) 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % Probability assessment (1) n/a 10 %- 30 % n/a 10 %- 30 % n/a (1) Probability assessment reflects management’s estimate an event occurring such that a forced exercise would occur resulting in a reduction in strike price. Valuation of short-term notes payable – Yorkville The Company elected the fair value option to account for the financial instrument with Yorkville signed on March 20, 2024 (see Note 6). The estimate of the fair value as of December 31, 2024 was determined using a binomial lattice model. The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. As of December 31, 2025, there was no outstanding balance related to the Yorkville debt. Changes in the fair value of debt that are accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses as a component of other income (expense) in the accompanying consolidated statements of operations and comprehensive loss under change in fair value of debt, with the exception of changes due to the Company’s credit risk, which are presented as a component of accumulated other comprehensive income in the accompanying consolidated balance sheets. The actual settlement of the short-term debt could differ from current estimates based on the timing of when and if Yorkville elects to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and movements in the Company’s common stock price. F- 20 The following table provides a rollforward of the aggregate fair values of the Company’s Yorkville debt for which fair values are determined using Level 3 inputs (in thousands): Balance as of January 1, 2025 $ 2,365 Addition of short-term notes payable - Principal repayments ( 2,145 ) Fair value adjustment ( 220 ) Balance as of December 31, 2025 - The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement: December 31, 2024 Expected term (years) 0.05 – 0.13 Volatility (annual) 100 % Risk-free rate 4.34 – 4.35 % Valuation of forward options in Yorkville SEPA The Yorkville SEPA is accounted for as a derivative and is recognized at fair value. Any changes in fair value between the carrying amount of the forward issuance contracts and the settlement amounts will be recognized in other income (expense) in the consolidated statement of operations and comprehensive loss. For the year ended December 31, 2025, the Company determined there were immaterial changes in derivative liability fair value related to the Yorkville SEPA. The Company recognized no change in derivative liability fair value for the year ended December 31, 2025. 4. RESEARCH AND DEVELOPMENT REVENUE For the years ended December 31, 2025 and 2024, the Company’s revenues disaggregated by the major sources was as follows (in thousands): Year Ended December 31, 2025 2024 BARDA $ 17,700 $ 27,903 Other U.S governmental authorities 1,950 1,678 Total revenue $ 19,650 $ 29,581 The following table presents the activity in the Company’s contract liabilities during the year ended December 31, 2025 (in thousands): December 31, 2024 Balance Additions Reductions December 31, 2025 Balance Contract liabilities: Deferred revenue $ 960 $ 4,721 $ ( 5,527 ) $ 154 Total contract liabilities $ 960 $ 4,721 $ ( 5,527 ) $ 154 F- 21 The following table presents the activity in the Company’s contract assets during the year ended December 31, 2025 (in thousands): December 31, 2024 Balance Additions Reductions December 31, 2025 Balance Contract assets: Unbilled revenue $ - $ 849 $ - $ 849 Total contract assets $ - $ 849 $ - $ 849 5. ACCRUED EXPENSES Accrued expenses consist of the following as of December 31, 2025 and December 31, 2024 (in thousands): December 31, December 31, 2025 2024 Salary and wages $ 1,762 $ 2,196 Operating expenses 81 355 Benefits 340 410 Taxes 98 188 Non-operating expenses 60 60 Total accrued expenses $ 2,341 $ 3,210 6. NOTES PAYABLE The Company entered into the Avenue Financing, the Yorkville agreement, the Related Party note, and financing arrangements for a portion of its Directors and Officers (“D&O”) insurance premiums, as follows (in thousands): Principal Repayments Outstanding Balance Amount Year Ended December 31, December 31, December 31, Financed Interest Rate 2025 2024 2025 2024 Avenue Capital Note Principal and Final Payment Fee $ 8,500 Prime + 5.25 % $ - $ - $ 9,250 $ - Yorkville Convertible Notes, at fair value 11,500 0.0 % 2,365 9,355 - 2,365 Related Party Note 1,000 8.0 % - 1,000 - - 2025 Insurance Note 580 8.0 % 154 - 426 - 2024 Insurance Note 596 8.4 % 422 174 - 422 New 2023 Insurance Note 631 8.6 % - 436 - - $ 2,941 $ 10,965 $ 9,676 $ 2,787 Less: current portion of notes payable ( 2,854 ) ( 2,787 ) Unamortized debt discounts and debt issuance costs ( 1,284 ) - Notes payable, long term $ 5,538 $ - Avenue Capital Financing On March 24, 2025, the Company completed the Avenue Financing, with an initial draw-down of $ 8.5 million. F- 22 The term of the Avenue Financing is for three years, with an interest-only payment period of no less than 15 months, which can be extended to 24 months upon achieving the milestones for the second financing tranche. The second financing tranche, which includes an additional $ 6.5 million in debt financing from Avenue Capital Group is contingent upon; (i) FDA clearance of the DeepView System and (ii) the Company completing a $ 7.0 million equity raise. The borrowings under the Avenue Financing accrue interest at a variable amount per annum equal to the greater of (i) the sum of (A) the Prime Rate plus (B) 5.25 %, and (ii) 12.75 %, and they mature on March 1, 2028 (the “Maturity Date”). In addition, on the Maturity Date a final payment of $ 0.8 million is due to Avenue Capital Group and is accrued as debt as of December 31, 2025. Up to $ 2.0 million of the borrowings under the Avenue Financing is convertible at the lenders option, into a number of shares of common stock at a price per share equal to 120 % of the exercise price of the Avenue Warrants discussed below. As part of the Avenue Financing the Company issued 768,072 warrants to Avenue Capital Group which was equal to 8.5 % of the total funding commitment (the “Avenue Warrants”). The Avenue Warrants have an exercise price equal to the lower of $ 1.66 per share and the lowest price per share paid to the Company in cash for common stock through December 31, 2025. The Avenue Warrants were determined to be classified as a liability instrument as certain terms preclude them from being considered indexed to the Company’s Common Stock. The net proceeds of Avenue Financing of $ 8.3 million were first allocated to the fair value of the Avenue Warrants, with the residual proceeds being allocated to the debt. The difference between debt proceeds and the amount of those proceeds allocated to debt gave rise to a debt discount of $ 0.7 million. The discount amount due to the Avenue Warrants of $ 0.7 million along with the loan fees allocated to the loan of $ 1.0 million, which includes the final payment of $ 0.8 million, for an aggregate debt discount and debt issuance costs of $ 1.7 million as shown in the table above, will be amortized as interest expense through maturity using the effective interest method. The portion of loan fees allocated to the Avenue Warrants, of $ 22,000 , were expensed during the year ended December 31, 2025 as financing related costs in the consolidated statement of operations and comprehensive income (loss). Future principal payments, including the final payment, of the Avenue note payable are as follows (in thousands): Year Ended December 31, 2026 $ 2,429 Year Ended December 31, 2027 4,857 Year Ended December 31, 2028 1,964 Total 9,250 Yorkville Convertible Notes On March 20, 2024, the Company entered into the SEPA with Yorkville pursuant to which the Company has the right to sell to Yorkville up to $ 30.0 million of its shares of Company Common Stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA (such transaction, the “Yorkville Transaction”). In connection with the SEPA, and subject to the conditions set forth therein, Yorkville has agreed to advance to the Company in the form of convertible promissory notes (the “Convertible Notes”) an aggregate principal amount of up to $ 12.5 million (the “Pre-Paid Advance”), which will be paid in three tranches. The first Pre-Paid Advance was disbursed on March 20, 2024 in the amount of $ 5.0 million with a fixed conversion price of $ 3.16 . The Company received $ 4.6 million in cash, net of the 8 % original issue discount. On May 14, 2024, the shareholders voted to approve the reservation and issuance of shares to Yorkville to exceed the Exchange Cap and the second Pre-Paid Advance was disbursed on May 16, 2024 in the amount of $ 4.6 million, which is the $ 5.0 million second Pre-Paid Advance net of $ 0.4 million of the 8 % original issue discount, with a fixed conversion price of $ 2.03 . The third Pre-Paid Advance was disbursed on July 17, 2024 in the principal amount of $ 2.3 million, which is the $ 2.5 million third Pre-Paid Advance net of the $ 0.2 million of the 8 % original issue discount, with a fixed conversion price equal to 120 % of the average VWAP during the three trading days immediately prior to the issuance of the note. The purchase price for the Pre-Paid Advance is 92.0 % of the principal amount of the Pre-Paid Advance. Interest shall accrue on the outstanding balance of any Pre-Paid Advance at an annual rate equal to 0 %, subject to an increase to 18 % upon an event of default as described in the Convertible Notes. The Company paid no interest relating to the Convertible Notes. F- 23 Beginning on the forty-fifth (45th) day following the issuance date of the Convertible Note issued in connection with the first Pre-Paid Advance, and continuing on the same day of each successive month thereafter, (each, an “Installment Date”), the Company shall repay a portion of the outstanding balance of the Pre-Paid Advance in an amount equal to (i) $ 1,750,000 , provided however, in respect of any Installment Date prior to the closing of the second Pre-Paid Advance, $ 750,000 (the “Installment Principal Amount”), plus (ii) the a payment premium of 7 % of such Installment Principal Amount, and (iii) accrued and unpaid interest hereunder as of each Installment Date. The maturity date of the Convertible Notes issued in connection with each Pre-Paid Advance will be 12 months after the issuance date of such Convertible Notes. In October 2024, the Company and Yorkville agreed to amend the dates and the allocation of installment amounts to be paid pursuant to the Pre-Paid Advances, such that the outstanding balance of the Pre-Paid Advances is to be paid by February 2025. During the year ended December 31, 2024, the Company made aggregate installment payments on the Pre-Paid Advances in the amount of $ 10.8 million, of which $ 8.3 million was settled in cash and $ 2.5 million was settled in shares. Of the aggregate installment payments, $ 9.4 million relates to the repayment of the principal, $ 0.8 million relates to the 8 % original issue discount and $ 0.6 million relates to the 7 % payment premium. As of December 31, 2024, the aggregate outstanding principal balance of the Yorkville Convertible Notes was $ 2.1 million. As the SEPA is an equity-linked contract that does not qualify for equity classification, any expenses incurred will be recognized in the consolidated statements of operations and comprehensive loss within financing related costs. For the year ended December 31, 2024, the Company recognized $ 1.1 million in issuance costs related to the SEPA. During the year ended December 31, 2025, the Company paid the remaining $ 2.4 million of Yorkville Convertible Notes of which $ 1.2 million was settled in cash and $ 1.2 million was settled in shares of common stock. The Company still has access to the remaining funds under the SEPA. The sales of the shares of Common Stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company’s option. Related Party Note On March 19, 2024, the Company announced that Spectral IP received a $ 1.0 million investment from an affiliate of its largest shareholder for the acquisition and development of a health care related artificial intelligence intellectual property portfolio. The investment is structured as a note payable with a one-year maturity, at an interest rate of 8 %, and requiring earlier prepayment if the Company spins off Spectral IP to the Company’s shareholders or if Spectral IP is sold to a third party. The holder of the Spectral IP Note exercised a number of conversion rights throughout the fourth quarter of 2024 for the full conversion of the Spectral IP Note in exchange for a total of 540,996 shares of the Company’s common stock, which represents a 5.00 % discount to the closing price of the Company’s shares of Common Stock on the day prior to the date of notice of the holder’s exercise of its conversion right. Insurance Notes The Company finances its director and officer liability insurance premiums over a term of less than one year. The Company has determined that the carrying amounts of all of the insurance notes approximate fair value due to the short-term nature of borrowings and current market rates of interest. 7. COMMITMENTS AND CONTINGENCIES Legal Matters The Company is not a party to any material legal proceedings or pending claims. The Company is aware of a material threatened claim that it believes is without merit. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities, none of which we believe are material or would be expected to have, individually or in the aggregate, a material adverse effect on our business, financial condition, cash flows or results of operations. F- 24 8. LEASES The Company leases office space for its principal office in Dallas, Texas, which was amended in April 2024 to extend the lease term to expire in February 2028. The lease amendment also included a landlord-provided tenant improvement allowance of up to $ 0.3 million to be applied to the costs of the construction of leasehold improvements. The Company determined that it owns the leasehold improvements under the lease and, as such, reflected the $ 0.3 million lease incentive as an in-substance fixed lease payment that reduced the lease liability and right-of-use asset. As of December 31, 2025, leasehold improvement costs of $ 0.3 million were incurred and paid for directly by the lessor. As construction was performed for the improvements, the reduction to the lease payments was capitalized to construction-in-process. The construction was completed during the year ended December 31, 2025 and the Company recognized a leasehold improvement asset which is amortized over the remaining lease term. During 2025, the Company entered into a lease for office space in the United Kingdom for annual payments of $ 0.1 million under a lease. The lease was renewed for an additional year in January 2026, however the Company has excluded this lease from the tables below as the term is twelve months . The following table summarizes quantitative information about the Company’s operating leases for the years ended December 31, 2025 and 2024 (in thousands): Year Ended December 31, 2025 2024 Operating cash flows used in operating leases $ 691 $ 894 Right-of-use assets exchanged for operating lease liabilities $ - $ 1,771 Weighted average remaining lease term (in years) 2.2 3.2 Weighted average discount rate 8.5 % 8.5 % The following table provides the components of the Company’s lease cost included in general and administrative expense in the consolidated statement of operations (in thousands): Year Ended December 31, 2025 2024 Operating leases Operating lease cost $ 727 $ 751 Variable lease cost 487 407 Operating lease expense 1,214 1,158 Short-term lease rent expense 145 149 Total rent expense $ 1,359 $ 1,307 Variable lease cost is primarily attributable to amounts paid to lessors for utility charges, parking, and property taxes under an office space lease. As of December 31, 2025, future minimum payments under the non-cancelable operating leases were as follows (in thousands): Year Ended December 31, 2026 $ 850 Year Ended December 31, 2027 871 Year Ended December 31, 2028 149 Total 1,870 Less: imputed interest ( 168 ) Operating lease liabilities $ 1,702 F- 25 9. STOCKHOLDERS’ EQUITY In conjunction with the Closing, the Company’s certificate of incorporation was amended and restated to authorize the issuance of 80,000,000 shares of Company Common Stock, $ 0.0001 par value and 1,000,000 shares of preferred stock, $ 0.0001 par value (the “Company Preferred Stock”). On March 21, 2025, the Company entered into Purchase Agreements with certain stockholders for the sale of an aggregate of 2,068,846 shares of Common Stock, at an offering price of $ 1.30 per Share along with the issuance of the Investor Warrants. The gross proceeds of $ 2.7 million were allocated to the liability-classified Investor Warrants based on their fair value at issuance of $ 2.2 million, with the residual gross proceeds of $ 0.5 million allocated to the Common Stock. Total issuance costs incurred of $ 0.2 million were allocated between the Investor Warrants and Common Stock issued. Issuance costs allocated to the Common Stock of $ 152,000 were recorded in additional paid-in-capital. On October 22, 2025, the Company entered into a securities purchase agreement with a certain investor for the sale of 3,065,000 shares of Common Stock, at an offering price of $ 1.90 per Share along with the issuance of the Hudson Warrants and Pre-Funded Warrants. The gross proceeds of $ 7.6 million were allocated to the liability-classified Hudson Warrants based on their fair value at issuance of $ 7.5 million, with the residual gross proceeds of $ 0.1 million allocated between the Common Stock and equity-classified Pre-Funded Warrants based on their relative fair value. Total issuance costs incurred of $ 0.6 million were allocated between the warrants and Common Stock issued. Issuance costs allocated to the Common Stock and Pre-Funded Warrants of less than $ 0.1 million were recorded in additional paid-in-capital. Refer to Note 2 for further information on the Investor Warrants, Avenue Warrants, and Pre-Funded Warrants. As described in Note 2, during the year ended December 31, 2025, 1,403,846 Investor Warrants were exercised for shares of Common Stock. In November and December 2024, the Company issued 2,415,900 shares for aggregate net proceeds of approximately $ 3.1 million to certain institutional investors through at-the market equity issuances. 10. STOCK-BASED COMPENSATION 2023 Long Term Incentive Plan On May 14, 2024, the Company’s shareholders approved the adoption of the 2023 Long Term Incentive Plan (the “2023 Plan”) which permits granting of incentive stock options (they must meet all statutory requirements), non-qualified stock options, stock appreciation rights, restricted stock, stock units, performance shares, performance units, incentive bonus awards, and other cash-based or stock-based awards. The options, restricted stock units and other securities issued pursuant to previous plans have been replaced with a corresponding award to be issued pursuant to the 2023 Plan. The maximum aggregate number of shares that may be issued under the Plan shall not exceed 8,000,000 , plus the number of shares that are automatically added on January 1st of each year for a period of up to ten years, commencing on January 1, 2024 and ending on (and including) January 1, 2033, in an amount equal to the lesser of (i) five percent ( 5 %) of the total number of shares of stock outstanding on December 31st of the preceding calendar year, and (ii) an amount determined by the Board of Directors. Pursuant to the 2023 Plan, stock options must expire within 10 years and must be granted with exercise prices of no less than the fair value of the common stock on the grant date, as determined by the Board of Directors. As of December 31, 2025, under the 2023 Plan, 3,857,136 shares of common stock were issuable upon exercise of outstanding options and 9,700 restricted stock units (“RSUs”) were issuable. Under the 2023 Plan, 3,730,684 shares remain available for issuance through grants of future options. The 2023 Plan provides that the Compensation Committee shall determine the vesting conditions of awards granted under the 2023 Plan, and the Compensation Committee has from time-to-time approved vesting schedules for certain awards that deviate from the vesting conditions described in the previous sentence. F- 26 Restricted Stock Units On January 3, 2024, the Company granted its then-CFO a market condition RSU of up to 150,000 shares of the Company’s common stock. The award had a grant date fair value of approximately $ 0.4 million using a Monte Carlo simulation model. The RSUs under this market-based award will vest partially based on achievement of stock price targets of the Company’s common stock. 50,000 RSUs vest when the 180-day VWAP meets or exceeds $ 8.00 per share, 50,000 RSUs vest when the 180-day VWAP meets or exceeds $ 12.00 per share, and 50,000 RSUs are not market-based and will vest over the continued service period of three years. These market-based conditions must be met in order for portions of the RSU award to vest, and it is therefore possible that certain awards ultimately would not vest. The grant date fair value of each RSU grant is expensed over the requisite service period. Compensation expense relating to share-based awards with market-based conditions is not reversed if these awards are forfeited based solely on failing to meet such market-based conditions. On February 29, 2024, the Company granted both its CFO and CEO awards of RSUs up to 150,000 shares of the Company’s common stock. The two awards had a grant date fair value of approximately $ 0.6 million using a Monte Carlo simulation model. The portion of RSUs that are market-based awards will vest partially based on achievement of stock price targets of the Company’s common stock. 37,500 RSUs vest when the 180-day VWAP meets or exceeds $ 8.00 per share, 37,500 RSUs vest when the 180-day VWAP meets or exceeds $ 10.00 per share. The market-based conditions must be met in order for the market-based portion of the RSU awards to vest, and it is therefore possible that certain awards ultimately would not vest. 75,000 RSUs are not market-based and will vest over the continued service period of three years. The grant date fair value of each RSU grant is expensed over the requisite service period. Compensation expense relating to share-based awards with market-based conditions is not reversed if these awards are forfeited based solely on failing to meet such market-based conditions. On February 29, 2024, the Company amended the terms of the January 3, 2024 RSU grant to its then-CFO to provide for identical vesting terms to those provided in the February 29, 2024 RSU grant. The Company determined the amended RSU grant represents a modification of the original award, however, the incremental compensation cost of the amendment was not material. In October 2024, in connection with the resignation of the then-CEO, 300,000 unvested RSUs were forfeited and the Company granted 100,000 RSUs that immediately vested to the then-CEO. During the year ended December 31, 2025, the Company modified the terms of 150,000 outstanding RSU awards with market based and service based vesting conditions to remove all market based vesting conditions and accelerate the service based vesting. The modified award will vest such that 100,000 awards vested upon modification and 50,000 awards will vest on December 31, 2025. The modification was accounted for as if the modified award was a new award on the modification date. The Company compared the fair-value-based measure of the modified awards to the fair-value-based measure of the original awards immediately before the modification. As a result of the modification, the Company recognized incremental compensation cost of approximately $ 43 thousand, representing the excess of the fair-value-based measure of the modified awards over the original awards. This incremental cost is being recognized over the remaining requisite service period of the awards. A summary of RSU activities for the year ended December 31, 2025 are presented below: Number of Shares Weighted Average Grant Date Fair Value per Share Nonvested as of January 1, 2025 169,400 $ 1.98 Granted - $ - Vested ( 159,700 ) $ 1.82 Forfeited - $ - Nonvested as of December 31, 2025 9,700 $ 0.45 F- 27 The Company did not grant any restricted stock awards during the year ended December 31, 2025. As of December 31, 2025, total unrecognized compensation expense related to restricted stock units was $ 13,000 , which is expected to be recognized over a weighted-average period of 0.3 years. Stock Options The fair value of each employee and non-employee stock option grant with service based vesting conditions is estimated on the date of grant using the Black-Scholes option-pricing model. In the current year, the Company estimates its expected stock volatility based on its historical volatility, and in previous years, due to insufficient historical volatility, the historical volatility of a publicly traded set of peer companies. The expected term of the Company’s stock options for employees has been determined utilizing the simplified method by taking an average of the vesting periods and the original contractual terms for each award. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the US. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company does not expect to pay any cash dividends in the foreseeable future. The Company’s stock options generally vest ratably annually over 3 years and have a contractual term of 10 years. In applying the Black Scholes option pricing model, the Company used the following assumptions for stock options granted during the years ended December 31, 2025 and 2024: Year ended December 31, 2025 Year ended December 31, 2024 Exercise price (per share) $ 1.28 $ 1.51 Expected term (years) 5.3 4.8 Volatility (annual) 89 % 66 % Risk-free rate 3.8 % 4.2 % Dividend yield (per share) 0 % 0 % During the year ended December 31, 2025, the Company granted stock options to purchase shares of the Company’s common stock to certain employees and board members which vest based on achievement of stock price targets of the Company’s common stock. As of December 31, 2025, options to purchase 550,000 shares of common stock will vest when the 30-day VWAP meets or exceeds $ 3.00 per share. The grant date fair value of these options were valued using a Monte Carlo valuation model and will be expensed over the requisite service period. In applying the Monte Carlo simulation model, the Company used the following assumptions for stock options granted during the years ended December 31, 2025: Year ended December 31, 2025 Exercise price (per share) $ 1.25 Expected term (years) 2.0 Volatility (annual) 75 % Risk-free rate 4.3 % Dividend yield (per share) 0 % F- 28 A summary of stock options activity for the year ended December 31, 2025 is presented below: Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2025 3,594,488 $ 2.01 6.0 $ 3,825 Options granted 918,706 1.26 Options forfeited ( 38,198 ) 2.82 Options cancelled ( 92,579 ) 3.97 Options exercised ( 525,277 ) 1.54 Outstanding as of December 31, 2025 3,857,136 1.84 6.1 544 Options vested and exercisable as of December 31, 2025 2,951,221 1.92 5.2 420 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the respective date. As of December 31, 2025, there was approximately $ 0.5 million of unrecognized stock-based compensation related to stock option grants that will be amortized over a weighted average period of 1 .0 years. The Company recorded stock-based compensation expense for stock options, RSUs, and restricted stock awards of $ 1.1 million for the year ended December 31, 2025 and $ 1.0 million for the year ended December 31, 2024 in general and administrative expenses in the consolidated statements of operations. 11. INCOME TAXES Effective for the year ended December 31, 2025, the Company adopted ASU 2023-09 and applied the disclosure requirements on a prospective basis. In accordance with prospective application, the Company did not recast prior period disclosures. Loss Before Income Taxes Loss from before income tax expense/(benefit) disaggregated between domestic and foreign were as follows in accordance with ASU 2023-09 (in thousands): 2025 Domestic ( 6,654 ) Foreign ( 906 ) Total loss before income taxes ( 7,560 ) Effective Tax Rate The overall effective tax rate “ETR” for the Company, as calculated under ASC 740 guidance for the tax period ended December 31,2025 and 2024 is ( 0.15 )% and ( 1.78 )% respectively. The following tables reconcile the federal statutory income rate to the Company’s effective income tax rate: 2025 U.S. federal statutory tax rate ( 1,588 ) 21.00 % State income taxes, net of federal benefit 72 ( 0.95 )% Foreign tax effects: United Kingdom: Changes in valuation allowance 227 ( 3.00 )% Statutory tax difference between U.K. and U.S. ( 36 ) 0.48 % Change in valuation allowance 1,908 ( 25.24 )% Nontaxable or nondeductible items: Mark to market warrants ( 682 ) 9.02 % Other 83 ( 1.10 )% Other: Other 27 ( 0.36 )% Total federal, state and income taxes 11 ( 0.15 )% F- 29 2024 Federal income tax rate 21.00 % State income tax benefit ( 0.65 )% Impact of non-U.S. Earnings ( 0.63 )% Permanent items ( 7.34 )% Return to provision adjustments ( 0.05 )% Non-deductible stock compensation ( 1.03 )% Non-deductible executive compensation ( 1.35 )% Tax Credits 0.16 % Difference and changes in tax rates 0.06 % Other 0.01 % Change in valuation allowance ( 11.9 )% Effective income tax rate ( 1.78 )% The main drivers between the federal statutory rate of 21.00 % and ETR of ( 0.15 %) for the year ended December 31, 2025 is the mark to market of the warrants and change in valuation allowance. Components of Income Tax Expense/(Benefit) The components of income tax expense/(benefit) for the years ended December 31, 2025 and 2024 are as follows (in thousands): 2025 2024 Current US Federal $ ( 82 ) $ 157 US State 93 114 Total current provision 11 271 Total provision for income taxes $ 11 $ 271 The company is in a taxable loss position for the year ending December 31, 2025. The current tax expense of $ 11,000 is resulting from the gross margin tax for the Company’s state filing in Texas. Income Taxes Paid Income taxes paid, net of refunds received, consisted of the following for the year ending December 31, 2025 (in thousands): 2025 Federal $ - State and local Texas 100 Income taxes paid, net of refunds received $ 100 F- 30 Deferred Income Taxes The main components of deferred tax assets/(liabilities) for the periods ended December 31, 2025 and 2024, are as follows (in thousands): 2025 2024 Deferred income tax assets: Net operating loss carryforwards $ 6,144 $ 4,518 Capitalized research expenses 598 870 Intangible assets 377 407 Stock-based compensation 377 337 Lease liabilities 357 - Tax credits 192 118 Non-deductible interest 186 - Accrued compensation 354 411 Other 12 - Total deferred income tax assets 8,597 6,661 Deferred income tax liabilities: Right-of-use assets ( 295 ) ( 412 ) Lease liabilities - ( 75 ) Total deferred income tax liabilities $ ( 295 ) $ ( 487 ) Net deferred income tax assets $ 8,302 $ 6,174 Valuation allowance ( 8,302 ) ( 6,174 ) Deferred income tax assets, net of valuation allowance - - Valuation Allowance Considerations ASC 740, “Income Taxes” requires that a valuation allowance be established when it is “more likely than not” that all, or a portion of, deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. After consideration of all the information available, management believes that uncertainty exists with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of December 31, 2025, and 2024. The net change in valuation allowance for the years ended December 31, 2025 and 2024 was an increase of $ 2.1 million and $ 1.8 million, respectively. Section 174 Capitalization On July 4, 2025, U.S. legislation formally titled “An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14” (“The Act”) was signed into law. The Act, among other things, extended key provisions of the 2017 Tax Cuts and Jobs Act and introduced targeted changes to the U.S. federal income tax regime. The most significant of these changes for the Company is the change to immediate expense for research and development costs that were previously capitalized and a change to the calculation for the interest limitation for tax purposes. During the year the Company recorded an immaterial benefit to income tax expense. The Company has also elected to deduct all 50 % of previously capitalized research and development expenses in 2025 and the balance in 2026, that resulted in an increase to net operating loss carryovers offset with a corresponding valuation allowance. The Company continues to capitalize certain research and development costs based on historic tax law. Net Operating Losses As of December 31, 2025 and 2024, the Company had available federal net operating loss carryforwards (“NOLs”) of $ 25.9 million and $ 19.2 million, respectively, which are available to offset future federal taxable income. Under the Tax Cuts and Jobs Act (“TCJA”), all NOLs incurred after December 31, 2017 are carried forward indefinitely for federal tax purposes. Utilization of net operating losses and credits may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses before utilization. The Company has not yet performed an analysis, and that, when completed, such an analysis may result in expiration of net operating losses before utilization and an adjustment to the Company’s deferred taxes. As of December 31, 2025 and 2024, the Company had available UK NOL of $ 2.8 million and $ 1.9 million to offset future UK taxable income. Section 382 of the Internal Revenue Code limits the utilization of U.S. net operating loss (“NOL”) carryforwards following a change of control. The Company has not performed an analysis of whether a change of control defined under Section 382 may have occurred. Upon performing an analysis of whether an ownership change has occurred, any future NOL deductions may be limited. However, the Company’s NOL carryforward as discussed above does not expire. F- 31 The Company is subject to taxation in the U.S and in various state, local and foreign jurisdictions. The Company’s tax returns for years 2021 through present are open to tax examinations by U.S. Federal, state, local and foreign tax authorities; however, carryforward attributes that were generated prior to January 1, 2018, remain subject to adjustment upon examination if they either have been utilized or will be utilized in a future period. 12. NET LOSS PER COMMON SHARE Basic and diluted net loss per common share attributable to common stockholders are the same for the years ended December 31, 2025 and 2024, since the inclusion of all potential shares of common stock outstanding would have been anti-dilutive due to the Company’s net loss. Basic and diluted net loss per common share attributable to common stockholders for the year ended December 31, 2025 includes the weighted average effect of 935,000 shares of common stock issuable upon exercise of pre-funded warrants that were issued in connection with the October 2025 Offering. The table below summarizes potentially dilutive securities that were excluded from the computation of net loss per common share as of the periods presented because including them would be anti-dilutive. 2025 2024 Common stock options 3,857,136 3,594,484 Common stock warrants 13,940,383 8,507,311 Unvested restricted stock units 9,700 169,400 Potentially dilutive securities 17,807,219 12,271,195 13. RELATED PARTY TRANSACTIONS On March 7, 2024, the Company formed a new wholly-owned subsidiary, Spectral IP, to be utilized to acquire artificial intelligence intellectual property with a specific emphasis on healthcare. On March 19, 2024, the Company announced that Spectral IP received a $ 1.0 million investment from an affiliate of its largest stockholder for the development of its artificial intelligence intellectual property portfolio. The investment was structured as a note payable with a one-year maturity, an interest rate of 8 %, and requiring earlier prepayment if the Company spins off Spectral IP to the Company’s stockholders or if Spectral IP is sold to a third party (the “Spectral IP Note”). On October 1, 2024, the Spectral IP Note was amended to (i) reduce the annual interest rate from 8 % to 4 %, (ii) extend the term of the Spectral IP Note through the second anniversary of the issuance date, March 18, 2026, (iii) include a conversion feature at the option of either the holder or Spectral IP to convert the then outstanding principal and accrued but unpaid interest into shares of the Company at any time (into such number of shares calculated by taking a five percent ( 5.00 %) discount to the closing price of the Common Stock on the day prior to the date of notice to the Company of the exercise of the conversion right) and at maturity, respectively, and (iv) provide for registration rights of any shares of the Company issued in satisfaction of the outstanding obligations. The holder of the Spectral IP Note exercised a number of conversion rights throughout the fourth quarter of 2024 for the full conversion of the Spectral IP Note in exchange for a total of 540,996 shares of the Common Stock, which represents a 5.00 % discount to the closing price of the Company’s shares of Common Stock on the day prior to the date of notice of the holder’s exercise of its conversion right. There were no outstanding obligations due and owing under the Spectral IP Note as of December 31, 2025. On November 4, 2024, Spectral IP entered into a purchase agreement with Sauvegarder Investment Management, Inc. (“Sauvegarder IM”, formerly known as SIM Tech Inc.), Sauvegarder IM was formed on March 25, 2024 with a focus on IP-related transactions. Pursuant to the purchase agreement, as amended, Spectral IP will acquire all of the outstanding common stock of Sauvegarder IM in exchange for issuing to the Sauvegarder IM stockholders 21,399,851 shares of common stock of Spectral IP and 22,827,380 shares of preferred stock of Spectral IP. Additionally, the Company has agreed to forfeit all shares of Spectral IP it holds other than 1,849,102 , which is the value the parties attribute to the intellectual property license agreement held by Spectral IP. On May 5, 2025, the Company entered into an intellectual property license agreement pursuant to which Spectral IP received a worldwide, non-exclusive, license to one international patent asset of the Company for the purposes of commercializing and monetizing outside the core areas of focus of the Company on market terms and conditions that are to be finalized. 14. SUBSEQUENT EVENTS On March 18, 2026, the Company announced that it has received a contract modification from the Biomedical Advanced Research and Development Authority (BARDA) for the advancement of $ 31.7 million from its existing contract with BARDA which included (i) a no-cost extension of the base phase of the contract, and (ii) the acceleration of certain parts of the next phase of such contract. As part of this funding advance, the Company has committed to fund $ 9.7 million of the total overall development costs associated with these feature advancements. This funding comes as part of an ongoing partnership with BARDA, which has committed $ 54.9 million to date under the contract with an overall value of approximately $ 150 million. F- 32 (b) Exhibits: The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K. Exhibit Index Exhibit Number Description 2.1†** Business Combination Agreement, by and among Rosecliff Acquisition Corp I, Merger Sub I, Merger Sub II and Spectral MD Holdings, Ltd., dated as of April 11, 2023 (incorporated by reference to Annex A of the Registration Statement on Form S-4 (File No. 333-271566)). 3.1** Second Amended and Restated Certificate of Incorporation of Spectral AI, Inc. (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on September 15, 2023). 3.2** Amended and Restated Bylaws of Spectral AI, Inc. (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on September 15, 2023). 4.1** Warrant Agreement, dated February 11, 2021, between Rosecliff Acquisition Corp I and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 17, 2021) 4.2** Description of the Registrant’s Securities (incorporated by reference to the Registrant’s Annual Report on Form 10-K filed on March 31, 2022) 4.3** Amended and Restated Registration Rights & Lock-up Agreement (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on September 15, 2023). 4.4** Registration Rights Agreement, dated December 26, 2023, between the Registrant and B. Riley Principal Capital II, LLC (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K filed with the SEC on December 27, 2023). 10.1** Form of Indemnification Agreement (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on September 15, 2023). 10.2** Sponsor Warrants Purchase Agreement, dated February 11, 2021, between the Registrant and the Sponsor (incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 17, 2021) 10.3** BARDA Award/Contract, July 1, 2019, by and between Spectral MD, Inc. and ASPR-BARDA (incorporated by reference to Exhibit 10.14 of the Registration Statement on Form S-4 (File No. 333-271566)). 10.4** Amendment of the Solicitation/Modification of the BARDA Contract, dated August 26, 2022, by and between Spectral MD, Inc. and ASPR-BARDA (incorporated by reference to Exhibit 10.15 of the Registration Statement on Form S-4 (File No. 333-271566)). 10.5** Award/Contract for DHA, dated July 1, 2021, by and between Spectral MD, Inc. and U.S. Army Medical Materiel Development Activity (incorporated by reference to Exhibit 10.16 of the Registration Statement on Form S-4 (File No. 333-271566)). 10.6** Amendment of the Solicitation/Modification of the DHA Contract, dated July 1, 2021, by and between Spectral MD, Inc. and U.S. Army medical Materiel Development Activity (incorporated by reference to Exhibit 10.17 of the Registration Statement on Form S-4 (File No. 333-271566)). 10.7** MTEC Research Project Award, dated April 12, 2023, by and between Spectral. MD, Inc. and Advanced Technology International MTEC Consortium Manager (incorporated by reference to Exhibit 10.18 of the Registration Statement on Form S-4 (File No. 333-271566)). 10.8** Sponsor Letter Agreement, dated April 11, 2023, by and among Rosecliff Acquisition I Sponsor LLC, Spectral MD Holdings, Ltd., and Rosecliff Acquisition Corp I (incorporated by reference to Annex F of the Registration Statement on Form S-4 (File No. 333-271566)). 10.9†** Common Stock Purchase Agreement, dated December 26, 2023, between the Registrant and B. Riley Principal Capital II, LLC (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the SEC on December 27, 2023). 72 10.10** Spectral MD, Inc. 2018 Long Term Incentive Plan (incorporated by referenced to Exhibit 99.1 of Registrant’s Registration Statement on Form S-8, filed with the SEC on February 9, 2024) 10.10.1** Form of Stock Option Award Agreement under Spectral MD, Inc. 2018 Long-Term Incentive Plan (incorporated by referenced to Exhibit 99.3 of Registrant’s Registration Statement on Form S-8, filed with the SEC on February 9, 2024) 10.10.2** Form of RSU Award Agreement under Spectral MD, Inc. 2018 Long-Term Incentive Plan (incorporated by referenced to Exhibit 99.4 of Registrant’s Registration Statement on Form S-8, filed with the SEC on February 9, 2024) 10.11** Spectral MD Holdings, Ltd. 2022 Long Term Incentive Plan (incorporated by referenced to Exhibit 99.2 of Registrant’s Registration Statement on Form S-8, filed with the SEC on February 9, 2024) 10.11.1** Form of Stock Option Award Agreement under Spectral MD Holdings, Ltd. 2022 Long-Term Incentive Plan (incorporated by referenced to Exhibit 99.5 of Registrant’s Registration Statement on Form S-8, filed with the SEC on February 9, 2024) 10.11.2** Form of RSU Award Agreement under Spectral MD Holdings, Ltd. 2022 Long-Term Incentive Plan (incorporated by referenced to Exhibit 99.6 of Registrant’s Registration Statement on Form S-8, filed with the SEC on February 9, 2024) 10.12** Spectral AI, Inc. 2023 Long Term Incentive Plan (Incorporated by reference to Exhibit 10.12 of Registrant’s Form 10-K, filed with the SEC on March 29, 2024) 14** Code of Business Conduct and Ethics (Incorporated by reference to Exhibit 14 of Registrant’s Form 10-K, filed with the SEC on March 29, 2024) 19 Insider Trading Policy 21 List of Subsidiaries of the Registrant as of December 31, 2025 23.1 Consent of Forvis Mazars, LLP. 23.2 Consent of KPMG LLP. 31.1 Certification of the Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002 31.2 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002 32.1 18 U.S.C. Section 1350 Certifications of the Principal Executive Officer and the Chief Financial Officer 97** Policy relating to recovery of erroneously awarded compensation (Incorporated by reference to Exhibit 97 of Registrant’s Form 10-K, filed with the SEC on March 29, 2024). 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File ** Previously filed. † Certain portions of this Exhibit have been omitted pursuant to Regulation S-K Item 601(a)(5), Item 601(a)(6) or Item 601(b)(10), as applicable, promulgated under the Exchange Act. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. Item 16. Form 10-K Summary. None. 73 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Signature Title Date /s/ Vincent S. Capone Chief Executive Officer March 24, 2026 Vincent S. Capone ( Principal Executive Officer ) /s/ Thomas Spieth Controller March 24 2026 Thomas Spieth ( Principal Financial Officer And Principal Accounting Officer ) /s/ J. Michael DiMaio Director March 24, 2026 J. Michael DiMaio /s/ Richard Cotton Director March 24, 2026 Richard Cotton /s/ Martin Mellish Director March 24, 2026 Martin Mellish /s/ Deepak Sadagopan Director March 24, 2026 Deepak Sadagopan /s/ Marion Snyder Director March 24, 2026 Marion Snyder 74